Приведен обзор литературы по механизму развития антифосфолипидного синдрома (АФС), тактика терапии. Представлены последние рекомендации Европейской антиревматической лиги (англ. European League Against Rheumatism, EULAR) по профилактике и лечению тромбозов при АФС. Обсуждены вопросы целесообразности терапии иммуносупрессивными препаратами при АФС.
The review is dedicated the development and the treatment of antiphospholipid syndrome (APS), and the content of the recent guidelines of European League Against Rheumatism (EULAR) for prevention and treatment of thrombosis in APS. The immunosuppressive therapy advisability in APS is discussed.
During the pandemics of COVID-19 associated with SARS-CoV-2, great attention in the medical community was devoted to the new clinical and basic issues of immune pathogenesis of human diseases. The detailed analysis of clinical signs and symptomes and immune disorders that occur in COVID-19 patients suggested that SARS-CoV-2 infection is associated with various extrapulmonary clinical manifestations and laboratory abnormalitites that are typical for immune-mediated rheumatic diseases. These data justified drug repurposing and the off-label administration of various medications specially designed for patients with immune-mediated rheumatic diseases for the treatment of COVID-19. The author reviews the prospects for administration of glucocorticoids, biologic agents, JAK inhibitors and other anti-cytokine agents in patients with COVID-19.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.